Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone for circadian rhythm sleep-wake disorder comorbid with bipolar depression
jRCTs071260015Recruiting
- Sponsor
- Sumitomo Pharma
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lurasidone in bipolar disorder (BD) and circadian rhythm sleep disorder (CRSD), sponsored by Sumitomo Pharma. Primary endpoint: Primary: Change in wake-up time (Fitbit). Started May 2026; status: recruiting.
02
Drugs
lurasidone
03
Conditions
bipolar disorder (BD)circadian rhythm sleep disorder (CRSD)
Beyond the preview
Go deeper on jRCTs071260015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071260015.